Precision oncology: lessons learned and challenges for the future

References

• Bentley DR, Balasubramanian S, Swerdlow HP, et al. Accurate whole human genome sequencing using reversible terminator chemistry. Nature. 2008;456(7218):53–59. doi:10.1038/nature0751718987734
   PubMed Web of Science ®Google Scholar
• Tennessen JA, Bigham AW, O’Connor TD, et al. Evolution and functional impact of rare coding variation from deep sequencing of human exomes. Science. 2012;337(6090):64–69. doi:10.1126/science.121924022604720
   PubMed Web of Science ®Google Scholar
• Genomes Project Consortium, Abecasis GR, Altshuler D, et al. A map of human genome variation from population-scale sequencing. Nature. 2010;467(7319):1061–1073. doi:10.1038/nature0953420981092
   PubMed Web of Science ®Google Scholar
• Yang Y, Muzny DM, Xia F, et al. Molecular findings among patients referred for clinical whole-exome sequencing. JAMA. 2014;312(18):1870–1879. doi:10.1001/jama.2014.1460125326635
   PubMed Web of Science ®Google Scholar
• Chong JX, Buckingham KJ, Jhangiani SN, et al. The genetic basis of mendelian phenotypes: discoveries, challenges, and opportunities. Am J Hum Genet. 2015;97(2):199–215. doi:10.1016/j.ajhg.2015.06.00926166479
   PubMed Web of Science ®Google Scholar
• Holm H, Gudbjartsson DF, Sulem P, et al. A rare variant in MYH6 is associated with high risk of sick sinus syndrome. Nat Genet. 2011;43(4):316–320. doi:10.1038/ng.78121378987
   PubMed Web of Science ®Google Scholar
• Do R, Stitziel NO, Won HH, et al. Exome sequencing identifies rare LDLR and APOA5 alleles conferring risk for myocardial infarction. Nature. 2015;518(7537):102–106. doi:10.1038/nature1391725487149
   PubMed Web of Science ®Google Scholar
• Steinberg S, Stefansson H, Jonsson T, et al. Loss-of-function variants in ABCA7 confer risk of Alzheimer’s disease. Nat Genet. 2015;47(5):445–447. doi:10.1038/ng.324625807283
   PubMed Web of Science ®Google Scholar
• Dewey FE, Murray MF, Overton JD, et al. Distribution and clinical impact of functional variants in 50,726 whole-exome sequences from the DiscovEHR study. Science. 2016;354:6319. doi:10.1126/science.aal1794
   Web of Science ®Google Scholar
• Gundem G, Perez-Llamas C, Jene-Sanz A, et al. IntOGen: integration and data mining of multidimensional oncogenomic data. Nat Methods. 2010;7(2):92–93. doi:10.1038/nmeth0210-9220111033
   PubMed Web of Science ®Google Scholar
• Dees ND, Zhang Q, Kandoth C, et al. MuSiC: identifying mutational significance in cancer genomes. Genome Res. 2012;22(8):1589–1598. doi:10.1101/gr.134635.11122759861
   PubMed Web of Science ®Google Scholar
• Lawrence MS, Stojanov P, Polak P, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013;499(7457):214–218. doi:10.1038/nature1221323770567
   PubMed Web of Science ®Google Scholar
• Handsaker RE, Korn JM, Nemesh J, McCarroll SA. Discovery and genotyping of genome structural polymorphism by sequencing on a population scale. Nat Genet. 2011;43(3):269–276. doi:10.1038/ng.76821317889
   PubMed Web of Science ®Google Scholar
• Zack TI, Schumacher SE, Carter SL, et al. Pan-cancer patterns of somatic copy number alteration. Nat Genet. 2013;45(10):1134–1140. doi:10.1038/ng.276024071852
   PubMed Web of Science ®Google Scholar
• Carter L, Rothwell DG, Mesquita B, et al. Molecular analysis of circulating tumor cells identifies distinct copy-number profiles in patients with chemosensitive and chemorefractory small-cell lung cancer. Nat Med. 2017;23(1):114–119. doi:10.1038/nm.423927869802
   PubMed Web of Science ®Google Scholar
• Nik-Zainal S, Alexandrov LB, Wedge DC, et al. Mutational processes molding the genomes of 21 breast cancers. Cell. 2012;149(5):979–993. doi:10.1016/j.cell.2012.04.02422608084
   PubMed Web of Science ®Google Scholar
• Alexandrov LB, Nik-Zainal S, Wedge DC, Campbell PJ, Stratton MR. Deciphering signatures of mutational processes operative in human cancer. Cell Rep. 2013;3(1):246–259. doi:10.1016/j.celrep.2012.12.00823318258
   PubMed Web of Science ®Google Scholar
• Alexandrov LB, Nik-Zainal S, Wedge DC, et al. Signatures of mutational processes in human cancer. Nature. 2013;500(7463):415–421. doi:10.1038/nature1247723945592
   PubMed Web of Science ®Google Scholar
• Waddell N, Pajic M, Patch AM, et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature. 2015;518(7540):495–501. doi:10.1038/nature1416925719666
   PubMed Web of Science ®Google Scholar
• Patch AM, Christie EL, Etemadmoghadam D, et al. Whole-genome characterization of chemoresistant ovarian cancer. Nature. 2015;521(7553):489–494. doi:10.1038/nature1441026017449
   PubMed Web of Science ®Google Scholar
• Nik-Zainal S, Davies H, Staaf J, et al. Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature. 2016;534(7605):47–54. doi:10.1038/nature1767627135926
   PubMed Web of Science ®Google Scholar
• Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374(23):2209–2221. doi:10.1056/NEJMoa151619227276561
   PubMed Web of Science ®Google Scholar
• Nik-Zainal S, Van Loo P, Wedge DC, et al. The life history of 21 breast cancers. Cell. 2012;149(5):994–1007. doi:10.1016/j.cell.2012.04.02322608083
   PubMed Web of Science ®Google Scholar
• Gibson WJ, Hoivik EA, Halle MK, et al. The genomic landscape and evolution of endometrial carcinoma progression and abdominopelvic metastasis. Nat Genet. 2016. doi:10.1038/ng.3602
   Web of Science ®Google Scholar
• Griffith M, Miller CA, Griffith OL, et al. Optimizing cancer genome sequencing and analysis. Cell Syst. 2015;1(3):210–223. doi:10.1016/j.cels.2015.08.01526645048
   PubMed Web of Science ®Google Scholar
• Zhang J, Walsh MF, Wu G, et al. Germline mutations in predisposition genes in pediatric cancer. N Engl J Med. 2015;373(24):2336–2346. doi:10.1056/NEJMoa150805426580448
   PubMed Web of Science ®Google Scholar
• Mandelker D, Zhang L, Kemel Y, et al. Mutation detection in patients with advanced cancer by universal sequencing of cancer-related genes in tumor and normal DNA vs guideline-based germline testing. JAMA. 2017;318(9):825–835. doi:10.1001/jama.2017.1113728873162
   PubMed Web of Science ®Google Scholar
• Huang K-L, Mashl RJ, Wu Y, et al. Pathogenic germline variants in 10,389 adult cancers. Cell. 2018;173(2):355–370.e14. doi:10.1016/j.cell.2018.03.03929625052
   PubMed Web of Science ®Google Scholar
• Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med. 2015;372(9):793–795. doi:10.1056/NEJMp150052325635347
   PubMed Web of Science ®Google Scholar
• Tannock IF, Hickman JA. Limits to personalized cancer medicine. N Engl J Med. 2016;375(13):1289–1294. doi:10.1056/NEJMsb160770527682039
   PubMed Web of Science ®Google Scholar
• Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405–424. doi:10.1038/gim.2015.3025741868
   PubMed Web of Science ®Google Scholar
• Aronson SJ, Rehm HL. Building the foundation for genomics in precision medicine. Nature. 2015;526(7573):336–342. doi:10.1038/nature1581626469044
   PubMed Web of Science ®Google Scholar
• Chen R, Shi L, Hakenberg J, et al. Analysis of 589,306 genomes identifies individuals resilient to severe Mendelian childhood diseases. Nat Biotechnol. 2016;34(5):531–538. doi:10.1038/nbt.351427065010
   PubMed Web of Science ®Google Scholar
• Telenti A, Pierce LC, Biggs WH, et al. Deep sequencing of 10,000 human genomes. Proc Natl Acad Sci U S A. 2016;113(42):11901–11906. doi:10.1073/pnas.161336511327702888
   PubMed Web of Science ®Google Scholar
• Parsons DW, Roy A, Yang Y, et al. Diagnostic yield of clinical tumor and germline whole-exome sequencing for children with solid tumors. JAMA Oncol. 2016. doi:10.1001/jamaoncol.2015.5699
   PubMed Web of Science ®Google Scholar
• Pinto N, Volchenboum SL, Skol AD, et al. Establishing a translational genomics infrastructure in pediatric cancer: the GREAT KIDS experience. Per Med. 2015;12(3):221–229. doi:10.2217/pme.14.9029771652
   PubMed Web of Science ®Google Scholar
• Worst BC, van Tilburg CM, Balasubramanian GP, et al. Next-generation personalised medicine for high-risk paediatric cancer patients – the INFORM pilot study. Eur J Cancer. 2016;65:91–101. doi:10.1016/j.ejca.2016.06.00927479119
   PubMed Web of Science ®Google Scholar
• Marron JM, DuBois SG, Glade Bender J, et al. Patient/parent perspectives on genomic tumor profiling of pediatric solid tumors: the Individualized Cancer Therapy (iCat) experience. Pediatr Blood Cancer. 2016;63(11):1974–1982. doi:10.1002/pbc.2613727429135
   PubMed Web of Science ®Google Scholar
• Harris MH, DuBois SG, Glade Bender JL, et al. Multicenter feasibility study of tumor molecular profiling to inform therapeutic decisions in advanced pediatric solid tumors: the Individualized Cancer Therapy (iCat) Study. JAMA Oncol. 2016. doi:10.1001/jamaoncol.2015.5689
   Web of Science ®Google Scholar
• Mody RJ, Wu YM, Lonigro RJ, et al. Integrative clinical sequencing in the management of refractory or relapsed cancer in youth. JAMA. 2015;314(9):913–925. doi:10.1001/jama.2015.1008026325560
   PubMed Web of Science ®Google Scholar
• Oberg JA, Glade Bender JL, Sulis ML, et al. Implementation of next generation sequencing into pediatric hematology-oncology practice: moving beyond actionable alterations. Genome Med. 2016;8(1):133. doi:10.1186/s13073-016-0389-628007021
   PubMedGoogle Scholar
• West HJ. Novel precision medicine trial designs: umbrellas and baskets. JAMA Oncol. 2017;3(3):423. doi:10.1001/jamaoncol.2016.529927930754
   PubMed Web of Science ®Google Scholar
• Linderman MD, Nielsen DE, Green RC. Personal genome sequencing in ostensibly healthy individuals and the PeopleSeq consortium. J Pers Med. 2016;6(2):14. doi:10.3390/jpm6020014
   PubMedGoogle Scholar
• Scollon S, Bergstrom K, Kerstein RA, et al. Obtaining informed consent for clinical tumor and germline exome sequencing of newly diagnosed childhood cancer patients. Genome Med. 2014;6(9):69. doi:10.1186/s13073-014-0069-325317207
   PubMed Web of Science ®Google Scholar
• Carey DJ, Fetterolf SN, Davis FD, et al. The Geisinger MyCode community health initiative: an electronic health record-linked biobank for precision medicine research. Genet Med. 2016;18(9):906–913. doi:10.1038/gim.2015.18726866580
   PubMed Web of Science ®Google Scholar
• Maissenhaelter BE, Woolmore AL, Schlag PM. Real-world evidence research based on big data: motivation-challenges-success factors. Onkologe (Berl). 2018;24(Suppl 2):91–98. doi:10.1007/s00761-018-0358-330464373
   PubMedGoogle Scholar
• Gottesman O, Kuivaniemi H, Tromp G, et al. The Electronic Medical Records and Genomics (eMERGE) Network: past, present, and future. Genet Med. 2013;15(10):761–771. doi:10.1038/gim.2013.7223743551
   PubMed Web of Science ®Google Scholar
• Bowton E, Field JR, Wang S, et al. Biobanks and electronic medical records: enabling cost-effective research. Sci Transl Med. 2014;6(234):234cm233. doi:10.1126/scitranslmed.3008604
   Web of Science ®Google Scholar
• Denny JC, Ritchie MD, Basford MA, et al. PheWAS: demonstrating the feasibility of a phenome-wide scan to discover gene-disease associations. Bioinformatics. 2010;26(9):1205–1210. doi:10.1093/bioinformatics/btq12620335276
   PubMed Web of Science ®Google Scholar
• Roden DM, Denny JC. Integrating electronic health record genotype and phenotype datasets to transform patient care. Clin Pharmacol Ther. 2016;99(3):298–305. doi:10.1002/cpt.32126667791
   PubMed Web of Science ®Google Scholar
• Verma A, Leader JB, Verma SS, et al. Integrating clinical laboratory measures and Icd-9 code diagnoses in phenome-wide association studies. Pac Symp Biocomput. 2016;21:168–179.26776183
   PubMedGoogle Scholar
• Schwartz ML, Williams MS, Murray MF. Adding protective genetic variants to clinical reporting of genomic screening results: restoring balance. JAMA. 2017;317:1527. doi:10.1001/jama.2017.153328288260
   PubMed Web of Science ®Google Scholar
• Shevchenko Y, Bale S. Clinical versus research sequencing. Cold Spring Harb Perspect Med. 2016;6(11):a025809. doi:10.1101/cshperspect.a02580927638353
   PubMed Web of Science ®Google Scholar
• Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009;361(2):123–134. doi:10.1056/NEJMoa090021219553641
   PubMed Web of Science ®Google Scholar
• Kalia SS, Adelman K, Bale SJ, et al. Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics. Genet Med. 2017;19(2):249–255. doi:10.1038/gim.2016.19027854360
   PubMed Web of Science ®Google Scholar
• Li Q, Wang K. InterVar: clinical interpretation of genetic variants by the 2015 ACMG-AMP guidelines. Am J Hum Genet. 2017;100(2):267–280. doi:10.1016/j.ajhg.2017.01.00428132688
   PubMed Web of Science ®Google Scholar
• Mateo J, Chakravarty D, Dienstmann R, et al. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). Ann Oncol. 2018;29:1895–1902. doi:10.1093/annonc/mdy26330137196
   PubMed Web of Science ®Google Scholar
• Chakravarty D, Gao J, Phillips SM, et al. OncoKB: a precision oncology knowledge base. JCO Precis Oncol. 2017;1:1–16. doi:10.1200/PO.17.00011
   Web of Science ®Google Scholar
• Griffith M, Spies NC, Krysiak K, et al. CIViC is a community knowledgebase for expert crowdsourcing the clinical interpretation of variants in cancer. Nat Genet. 2017;49(2):170–174. doi:10.1038/ng.377428138153
   PubMed Web of Science ®Google Scholar
• Wagner AH, Walsh B, Mayfield G, et al. A harmonized meta-knowledgebase of clinical interpretations of cancer genomic variants. bioRxiv. 2018. doi:10.1101/366856
   Google Scholar
• Emamekhoo H, Lang JM. Are liquid biopsies ready for primetime? Cancer. 2019;125(6):834–837. doi:10.1002/cncr.3164430582152
   PubMed Web of Science ®Google Scholar
• Campos CDM, Jackson JM, Witek MA, Soper SA. Molecular profiling of liquid biopsy samples for precision medicine. Cancer J. 2018;24(2):93–103. doi:10.1097/PPO.000000000000031129601336
   PubMed Web of Science ®Google Scholar
• Voest EE, Bernards R. DNA-guided precision medicine for cancer: a case of irrational exuberance? Cancer Discov. 2016;6(2):130–132. doi:10.1158/2159-8290.CD-15-132126851184
   PubMed Web of Science ®Google Scholar
• Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351(4):337–345. doi:10.1056/NEJMoa03302515269313
   PubMed Web of Science ®Google Scholar
• Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008;359(17):1757–1765. doi:10.1056/NEJMoa080438518946061
   PubMed Web of Science ®Google Scholar
• De Roock W, Claes B, Bernasconi D, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 2010;11(8):753–762. doi:10.1016/S1470-2045(10)70130-320619739
   PubMed Web of Science ®Google Scholar
• Lesurf R, Griffith OL, Griffith M, et al. Genomic characterization of HER2-positive breast cancer and response to neoadjuvant trastuzumab and chemotherapy-results from the ACOSOG Z1041 (Alliance) trial. Ann Oncol. 2017;28(5):1070–1077. doi:10.1093/annonc/mdx04828453704
   PubMed Web of Science ®Google Scholar
• Solomon BJ, Mok T, Kim DW, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014;371(23):2167–2177. doi:10.1056/NEJMoa140844025470694
   PubMed Web of Science ®Google Scholar
• Shaw AT, Solomon BJ. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med. 2015;372(7):683–684. doi:10.1056/NEJMc1415359
   PubMed Web of Science ®Google Scholar
• Von Hoff DD, Stephenson JJ Jr, Rosen P, et al. Pilot study using molecular profiling of patients’ tumors to find potential targets and select treatments for their refractory cancers. J Clin Oncol. 2010;28(33):4877–4883. doi:10.1200/JCO.2009.26.598320921468
   PubMed Web of Science ®Google Scholar
• Kim ES, Herbst RS, Wistuba II, et al. The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov. 2011;1(1):44–53. doi:10.1158/2159-8274.CD-10-001022586319
   PubMed Web of Science ®Google Scholar
• Le Tourneau C, Delord JP, Goncalves A, et al. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. Lancet Oncol. 2015;16(13):1324–1334. doi:10.1016/S1470-2045(15)00188-626342236
   PubMed Web of Science ®Google Scholar
• Meric-Bernstam F, Brusco L, Shaw K, et al. Feasibility of large-scale genomic testing to facilitate enrollment onto genomically matched clinical trials. J Clin Oncol. 2015;33(25):2753–2762. doi:10.1200/JCO.2014.60.416526014291
   PubMed Web of Science ®Google Scholar
• Le Tourneau C, Paoletti X, Servant N, et al. Randomised proof-of-concept phase II trial comparing targeted therapy based on tumour molecular profiling vs conventional therapy in patients with refractory cancer: results of the feasibility part of the SHIVA trial. Br J Cancer. 2014;111(1):17–24. doi:10.1038/bjc.2014.21124762958
   PubMed Web of Science ®Google Scholar
• Hyman DM, Taylor BS, Baselga J. Implementing genome-driven oncology. Cell. 2017;168(4):584–599. doi:10.1016/j.cell.2016.12.01528187282
   PubMed Web of Science ®Google Scholar
• Ding L, Ley TJ, Larson DE, et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature. 2012;481(7382):506–510. doi:10.1038/nature1073822237025
   PubMed Web of Science ®Google Scholar
• Welch JS, Ley TJ, Link DC, et al. The origin and evolution of mutations in acute myeloid leukemia. Cell. 2012;150(2):264–278. doi:10.1016/j.cell.2012.06.02322817890
   PubMed Web of Science ®Google Scholar
• Landau DA, Carter SL, Stojanov P, et al. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell. 2013;152(4):714–726. doi:10.1016/j.cell.2013.01.01923415222
   PubMed Web of Science ®Google Scholar
• Suzuki H, Aoki K, Chiba K, et al. Mutational landscape and clonal architecture in grade II and III gliomas. Nat Genet. 2015;47(5):458–468. doi:10.1038/ng.327325848751
   PubMed Web of Science ®Google Scholar
• Gundem G, Van Loo P, Kremeyer B, et al. The evolutionary history of lethal metastatic prostate cancer. Nature. 2015;520(7547):353–357. doi:10.1038/nature1434725830880
   PubMed Web of Science ®Google Scholar
• McPherson A, Roth A, Laks E, et al. Divergent modes of clonal spread and intraperitoneal mixing in high-grade serous ovarian cancer. Nat Genet. 2016;48(7):758–767. doi:10.1038/ng.357327182968
   PubMed Web of Science ®Google Scholar
• Gerstung M, Beisel C, Rechsteiner M, et al. Reliable detection of subclonal single-nucleotide variants in tumour cell populations. Nat Commun. 2012;3:811. doi:10.1038/ncomms181422549840
   PubMed Web of Science ®Google Scholar
• Kivioja T, Vaharautio A, Karlsson K, et al. Counting absolute numbers of molecules using unique molecular identifiers. Nat Methods. 2011;9(1):72–74. doi:10.1038/nmeth.177822101854
   PubMed Web of Science ®Google Scholar
• Kennedy SR, Schmitt MW, Fox EJ, et al. Detecting ultralow-frequency mutations by Duplex Sequencing. Nat Protoc. 2014;9(11):2586–2606. doi:10.1038/nprot.2014.17025299156
   PubMed Web of Science ®Google Scholar
• Cortot AB, Janne PA. Molecular mechanisms of resistance in epidermal growth factor receptor-mutant lung adenocarcinomas. Eur Respir Rev. 2014;23(133):356–366. doi:10.1183/09059180.0000461425176972
   PubMedGoogle Scholar
• Sequist LV, Soria JC, Goldman JW, et al. Rociletinib in EGFR-mutated non-small-cell lung cancer. N Engl J Med. 2015;372(18):1700–1709. doi:10.1056/NEJMoa141365425923550
   PubMed Web of Science ®Google Scholar
• Piotrowska Z, Niederst MJ, Karlovich CA, et al. Heterogeneity underlies the emergence of EGFRT790 wild-type clones following treatment of T790M-positive cancers with a third-generation EGFR inhibitor. Cancer Discov. 2015;5(7):713–722. doi:10.1158/2159-8290.CD-15-039925934077
   PubMed Web of Science ®Google Scholar
• Abbosh C, Birkbak NJ, Wilson GA, et al. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature. 2017;545(7655):446–451. doi:10.1038/nature2236428445469
   PubMed Web of Science ®Google Scholar
• Genomes Project Consortium, Auton A, Brooks LD, et al. A global reference for human genetic variation. Nature. 2015;526(7571):68–74. doi:10.1038/nature1539326432245
   PubMed Web of Science ®Google Scholar
• Henderson TO, Bhatia S, Pinto N, et al. Racial and ethnic disparities in risk and survival in children with neuroblastoma: a Children’s Oncology Group study. J Clin Oncol. 2011;29(1):76–82. doi:10.1200/JCO.2010.29.610321098321
   PubMed Web of Science ®Google Scholar
• Gamazon ER, Pinto N, Konkashbaev A, et al. Trans-population analysis of genetic mechanisms of ethnic disparities in neuroblastoma survival. J Natl Cancer Inst. 2013;105(4):302–309. doi:10.1093/jnci/djs50323243203
   PubMedGoogle Scholar
• Edwards SL, Beesley J, French JD, Dunning AM. Beyond GWASs: illuminating the dark road from association to function. Am J Hum Genet. 2013;93(5):779–797. doi:10.1016/j.ajhg.2013.10.01224210251
   PubMed Web of Science ®Google Scholar
• Asimit JL, Hatzikotoulas K, McCarthy M, Morris AP, Zeggini E. Trans-ethnic study design approaches for fine-mapping. Eur J Hum Genet. 2016;24(9):1330–1336. doi:10.1038/ejhg.2016.126839038
   PubMed Web of Science ®Google Scholar
• Hungate EA, Vora SR, Gamazon ER, et al. A variant at 9p21.3 functionally implicates CDKN2B in paediatric B-cell precursor acute lymphoblastic leukaemia aetiology. Nat Commun. 2016;7:10635. doi:10.1038/ncomms1063526868379
   PubMed Web of Science ®Google Scholar
• Ainscough BJ, Barnell EK, Ronning P, et al. A deep learning approach to automate refinement of somatic variant calling from cancer sequencing data. Nat Genet. 2018;50(12):1735–1743. doi:10.1038/s41588-018-0257-y30397337
   PubMed Web of Science ®Google Scholar
• Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 2010;38(16):e164. doi:10.1093/nar/gkq60320601685
   PubMed Web of Science ®Google Scholar
• McLaren W, Gil L, Hunt SE, et al. The ensembl variant effect predictor. Genome Biol. 2016;17(1):122. doi:10.1186/s13059-016-0974-427268795
   PubMed Web of Science ®Google Scholar
• Yang HT, Ju JH, Wong YT, Shmulevich I, Chiang JH. Literature-based discovery of new candidates for drug repurposing. Brief Bioinform. 2017;18(3):488–497. doi:10.1093/bib/bbw03027113728
   PubMed Web of Science ®Google Scholar
• Chang MT, Asthana S, Gao SP, et al. Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. Nat Biotechnol. 2016;34(2):155–163. doi:10.1038/nbt.339126619011
   PubMed Web of Science ®Google Scholar
• Bertotti A, Papp E, Jones S, et al. The genomic landscape of response to EGFR blockade in colorectal cancer. Nature. 2015;526(7572):263–267. doi:10.1038/nature1496926416732
   PubMed Web of Science ®Google Scholar
• Uzilov AV, Ding W, Fink MY, et al. Development and clinical application of an integrative genomic approach to personalized cancer therapy. Genome Med. 2016;8(1):62. doi:10.1186/s13073-016-0313-027245685
   PubMed Web of Science ®Google Scholar
• Lek M, Karczewski KJ, Minikel EV, et al. Analysis of protein-coding genetic variation in 60,706 humans. Nature. 2016;536(7616):285–291. doi:10.1038/nature1905727535533
   PubMed Web of Science ®Google Scholar
• Ruderfer DM, Hamamsy T, Lek M, et al. Patterns of genic intolerance of rare copy number variation in 59,898 human exomes. Nat Genet. 2016;48(10):1107–1111. doi:10.1038/ng.363827533299
   PubMed Web of Science ®Google Scholar
• Tarailo-Graovac M, Zhu JYA, Matthews A, van Karnebeek CDM, Wasserman WW. Assessment of the ExAC data set for the presence of individuals with pathogenic genotypes implicated in severe Mendelian pediatric disorders. Genet Med. 2017. doi:10.1038/gim.2017.50
   PubMed Web of Science ®Google Scholar
• The Clinical Cancer Genome Task Team of the Global Alliance for Genomics and Health. Sharing clinical and genomic data on cancer – the need for global solutions. N Engl J Med. 2017;376(21):2006–2009. doi:10.1056/NEJMp161225428538124
   PubMed Web of Science ®Google Scholar
• Weinshilboum RM, Wang L. Pharmacogenomics: precision medicine and drug response. Mayo Clin Proc. 2017;92(11):1711–1722. doi:10.1016/j.mayocp.2017.09.00129101939
   PubMed Web of Science ®Google Scholar
• Steuer CE, Ramalingam SS. Tumor mutation burden: leading immunotherapy to the Era of precision medicine? J Clin Oncol. 2018;36(7):631–632. doi:10.1200/JCO.2017.76.877029337637
   PubMed Web of Science ®Google Scholar
• Moran S, Martinez-Cardus A, Boussios S, Esteller M. Precision medicine based on epigenomics: the paradigm of carcinoma of unknown primary. Nat Rev Clin Oncol. 2017;14(11):682–694. doi:10.1038/nrclinonc.2017.9728675165
   PubMed Web of Science ®Google Scholar
• AACR Project GENIE Consortium. AACR project GENIE: powering precision medicine through an international consortium. Cancer Discov. 2017;7(8):818–831. doi:10.1158/2159-8290.CD-17-015128572459
   PubMed Web of Science ®Google Scholar
• Rothwell DG, Ayub M, Cook N, et al. Utility of ctDNA to support patient selection for early phase clinical trials: the TARGET study. Nat Med. 2019;25(5):738–743. doi:10.1038/s41591-019-0380-z31011204
   PubMed Web of Science ®Google Scholar
• Sicklick JK, Kato S, Okamura R, et al. Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study. Nat Med. 2019;25(5):744–750. doi:10.1038/s41591-019-0407-531011206
   PubMed Web of Science ®Google Scholar
• Rodon J, Soria JC, Berger R, et al. Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial. Nat Med. 2019;25(5):751–758. doi:10.1038/s41591-019-0424-431011205
   PubMed Web of Science ®Google Scholar
• Le Tourneau C, Borcoman E, Kamal M. Molecular profiling in precision medicine oncology. Nat Med. 2019;25(5):711–712. doi:10.1038/s41591-019-0442-231036881
   PubMed Web of Science ®Google Scholar